TICKERNERD
Menu
ICUICUHealthcare · Biotechnology

ICU Stock Forecast: Seastar Medical Holding Corp. Price Predictions for 2026-2027

Last close, 21 Oct 2026
$3.17
+3.93% on the day

The 1 Wall Street analysts covering Seastar Medical Holding Corp. hold a median 12-month price target of $10 — +215.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$16.0M
Ticker Nerd rank
23/ 100
Median analyst target
$10
Analysts covering
1
Revenue$615K+82.0% y/y
Operating income−$3.8M
Net income−$3.7M
Free cash flow−$3.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.3%
1M
−11.5%
YTD
+32.1%
1Y
−49.7%
From 52W high
−49.8%
From 52W low
+43.4%
$2.21
$6.31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ICU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seastar Medical Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
23/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Growth
80
Revisions
50
Accruals
27
Momentum
25
Volatility
23
Quality
22
Value
13
Issuance
12

Size (89): Smaller than most of the companies we track.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ICU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26ICUHigh $12Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $8Median $10High $12

The green dot is the last close — the median target sits +215.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026Maxim GroupMaintainsBuy$6.00 → $8.00
20 Apr 2023Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ICU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

ICU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Oct 2026, Seastar Medical Holding Corp. returned −49.7% against +16.4% for the S&P 500, dividends included.

ICU vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ICUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Seastar Medical Holding Corp. (ICU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 81% of US stocks

Price / sales
9.4×

Cheaper than 14% of US stocks

Price / book
3.0×

Cheaper than 30% of US stocks

EV / EBITDA
−0.5×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
82.0%

Higher than 91% of US stocks

Earnings growth (YoY)
82.0%

Higher than 81% of US stocks

Gross margin
91.2%

Higher than 97% of US stocks

Operating margin
−616.4%

Higher than 7% of US stocks

Net margin
95.7%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−356.9%

Higher than 4% of US stocks

Return on assets
−102.7%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Seastar Medical Holding Corp. (ICU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Seastar Medical Holding Corp. has a market value of $16.0M and an enterprise value of $6.7M.

  • Revenue in the twelve months to 30 June 2026: $1.7M. The latest quarter grew 82.0% year on year.

  • Net income over the same four quarters: −$13.6M, a −795.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.91.

  • Free cash flow in the twelve months to 30 June 2026: −$13.7M.

  • Shares outstanding: 4.3M.

  • Trailing P/E: −0.5×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Seastar Medical Holding Corp. employs 18 people — $95K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Oct 2026

Data provided by Twelve Data

Peers

ICU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ICUSeastar Medical Holding Corp.$16.0M23
ALLRAllarity Therapeutics, Inc.$14.1M31
TVRDTvardi Therapeutics, Inc.$13.6M36
ACTUActuate Therapeutics, Inc.$13.5M36
BCDABioCardia, Inc.$14.6M43
TCRXTScan Therapeutics, Inc.$14.6M54
DAREDaré Bioscience, Inc.$13.3M31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seastar Medical Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ICU news & analysis

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI

GlobeNewsWire · 22 Oct 2026positive

SeaStar Medical reported that patients treated with QUELIMMUNE in its post-approval SAVE registry analysis had statistically significantly higher survival at Day 60, Day 90, and hospital discharge than a comparator cohort. The company also reported no device-related adverse events in treated patients.

Why it matters — The findings concern survival outcomes and device-related adverse events for QUELIMMUNE in pediatric sepsis-associated acute kidney injury.

SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award

GlobeNewsWire · 14 Oct 2026positive

SeaStar Medical Chief Medical Officer Kevin Chung, MD, was named the 2026 recipient of the Combat Nephrology Award. The award recognizes his career in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support.

Why it matters — The recognition highlights the experience of a SeaStar Medical executive in fields relevant to the company’s area of focus.

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

GlobeNewsWire · 7 Oct 2026positive

The FDA granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device therapy to treat hyperinflammation in adults with sepsis or a septic condition. The designation is intended to support accelerated development, assessment, and FDA review.

Why it matters — ICU watchers may note the regulatory designation as a development milestone for the company’s SCD therapy.

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

GlobeNewsWire · 5 Oct 2026neutral

SeaStar Medical announced it entered into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to 854,002 shares of common stock at a reduced exercise price of $3.866 per share, generating approximately $3.3 million in gross proceeds before fees and expenses.

Why it matters — This capital raise provides ICU with additional funding proceeds from existing warrant holders, which is relevant to watchers monitoring the company's liquidity and financing activity.

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

GlobeNewsWire · 2 Oct 2026positive

SeaStar Medical announced that a late-breaking abstract evaluating results from the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the American Society of Nephrology (ASN) Kidney Week 2026, to be held in Denver, CO, October 21–25, 2026.

Why it matters — An acceptance of its SAVE Registry data for a late-breaking presentation at a major nephrology conference highlights SeaStar Medical's clinical visibility within the kidney-care community.

FAQ

Frequently asked questions about ICU stock

What is the ICU stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Seastar Medical Holding Corp. have a median 12-month price target of $10, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICU stock a buy right now?

Of the 1 analysts covering Seastar Medical Holding Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seastar Medical Holding Corp. 23 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICU?

As at 21 Oct 2026, Seastar Medical Holding Corp. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will ICU stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +215.5% from the last close, and Ticker Nerd's factor model ranks Seastar Medical Holding Corp. 23 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICU stock forecast for 2030?

No analyst covering Seastar Medical Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.

How has ICU stock performed over the past year?

Seastar Medical Holding Corp. returned -49.7% over the 12 months to 21 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Seastar Medical Holding Corp. do?

SeaStar Medical Holding Corporation is a commercial-stage medical device company focused on therapies for critically ill patients facing organ failure and severe inflammatory conditions. SeaStar Medical develops and commercializes extracorporeal treatment systems centered on its Selective Cytopheretic Device platform, which is designed to modulate harmful immune responses and reduce hyperinflammation.

What is the latest news on ICU?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI". SeaStar Medical reported that patients treated with QUELIMMUNE in its post-approval SAVE registry analysis had statistically significantly higher survival at Day 60, Day 90, and hospital discharge than a comparator cohort. The company also reported no device-related adverse events in treated patients.

Company

About Seastar Medical Holding Corp.

SeaStar Medical Holding Corporation is a commercial-stage medical device company focused on therapies for critically ill patients facing organ failure and severe inflammatory conditions. SeaStar Medical develops and commercializes extracorporeal treatment systems centered on its Selective Cytopheretic Device platform, which is designed to modulate harmful immune responses and reduce hyperinflammation. The company’s current product portfolio includes QUELIMMUNE, an FDA-approved treatment for pediatric acute kidney injury associated with sepsis or septic condition requiring renal replacement therapy, along with additional SCD-based programs in adult kidney injury and other serious inflammatory indications. Based in Denver, Colorado, SeaStar Medical operates in the medical technology and specialty devices market, addressing unmet needs in hospital intensive care and renal replacement settings.

CEO Mr. Eric Schlorff · 18 employees · United States · https://seastarmedical.com